Views from a vaccine manufacturer: Q&A - Abdul Muktadir, Incepta Pharmaceuticals; Pandemic Treaty Action
Newsletter Edition #43 [The Weekly Primer]
Far away from Geneva, some developing countries are vying to become the next big vaccine manufacturing powerhouse. With India facing surging infections caused by SARS-CoV-2 and its variants, the pressure on Indian manufacturers to retain vaccine doses for India and the neighborhood will only increase, notwithstanding contractual commitments with West…
Keep reading with a 7-day free trial
Subscribe to Geneva Health Files to keep reading this post and get 7 days of free access to the full post archives.